Cancer Immunotherapy Meets Oncology In Honor of Christoph Huber /

This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and reg...

Full description

Corporate Author: SpringerLink (Online service)
Other Authors: Britten, Cedrik Michael. (Editor, http://id.loc.gov/vocabulary/relators/edt), Kreiter, Sebastian. (Editor, http://id.loc.gov/vocabulary/relators/edt), Diken, Mustafa. (Editor, http://id.loc.gov/vocabulary/relators/edt), Rammensee, Hans-Georg. (Editor, http://id.loc.gov/vocabulary/relators/edt)
Language:English
Published: Cham : Springer International Publishing : Imprint: Springer, 2014.
Edition:1st ed. 2014.
Subjects:
Online Access:https://doi.org/10.1007/978-3-319-05104-8
LEADER 04554nam a22005535i 4500
001 978-3-319-05104-8
003 DE-He213
005 20210703131337.0
007 cr nn 008mamaa
008 140423s2014 gw | s |||| 0|eng d
020 |a 9783319051048  |9 978-3-319-05104-8 
024 7 |a 10.1007/978-3-319-05104-8  |2 doi 
050 4 |a RC254-282 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Cancer Immunotherapy Meets Oncology  |h [electronic resource] :  |b In Honor of Christoph Huber /  |c edited by Cedrik Michael Britten, Sebastian Kreiter, Mustafa Diken, Hans-Georg Rammensee. 
250 |a 1st ed. 2014. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2014. 
300 |a XX, 246 p. 19 illus., 18 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Immunological and Regulatory Framework for Immuno-Oncology: From Basic Immunology to New Therapies for Patients -- How T cells single out tumor cells: 'and that has made all the difference' -- Tregs and Immune Inhibition -- Regulatory Landscape for Cancer Immunotherapy -- Immunoguiding -- Onco-Immunology Framework and Immunomodulatory Antibodies -- Immunotherapies: Peptide-based Vaccines and HPV Malignancies.- Dendritic cell based cancer vaccines.- RNA Vaccines and Personalized Medicine Approaches.-Antibody Therapy in Oncology.- Engineered Antibodies to Engage Immune Cells to the Tumor -- TCRs and TCR Therapy -- CAR Therapy.- Cancer Entities: Melanoma -- Prostate Cancer/Sipuleucel and RNA Vaccines -- Recent advances in the immunotherapy of renal cell cancer and other solid tumors -- Gastric Cancer -- NSCLC -- Breaking tolerance by allogeneic lymphocyte therapy.- Biomarkers: Exploring Immunogenic Cell Death for Patient Benefit -- Circulating Tumor Cells -- Genomics Meets Oncology -- Featured Chapters: Oncolytic Viruses -- Pharma View on Immunotherapy -- Final Remarks. 
520 |a This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing.   Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients. 
650 0 |a Oncology  . 
650 0 |a Cancer research. 
650 0 |a Pharmacology. 
650 0 |a Immunology. 
650 1 4 |a Oncology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/H33160 
650 2 4 |a Cancer Research.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B11001 
650 2 4 |a Pharmacology/Toxicology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B21007 
650 2 4 |a Immunology.  |0 https://scigraph.springernature.com/ontologies/product-market-codes/B14000 
700 1 |a Britten, Cedrik Michael.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Kreiter, Sebastian.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Diken, Mustafa.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Rammensee, Hans-Georg.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783319051031 
776 0 8 |i Printed edition:  |z 9783319051055 
776 0 8 |i Printed edition:  |z 9783319381268 
856 4 0 |u https://doi.org/10.1007/978-3-319-05104-8 
912 |a ZDB-2-SME 
912 |a ZDB-2-SXM 
950 |a Medicine (SpringerNature-11650) 
950 |a Medicine (R0) (SpringerNature-43714)